Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975371 · ClinicalTrials.gov registry record
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 1,415
- Enrollment target
NCT06975371: Completed study, sponsored by Daiichi Sankyo.
NCT06975371 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,415 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06975371 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 1,415 participants
- Enrollment target
Study Summary
This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
Primary Outcome
Real-world progression-free survival (rwPFS) will be calculated as the time from the index treatment date to the date of the first documented rwP event occurring \>14 days after the index treatment date or date of death, whichever occurs first.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2025-08-05 |
What the finished NCT06975371 record still lists
NCT06975371 is an observational study that tracks outcomes without assigning an intervention. Its 1,415 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06975371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06975371 about?
NCT06975371 is a clinical study titled "Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i". This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
What is the current status of trial NCT06975371?
This trial is currently completed. The enrollment target is 1,415 participants. The study started on 2025-04-14. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT06975371?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06975371?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05890404 · 1,410 participants · NA
SGM Evidenced-Based Mental Healthcare Implementation
- NCT07042451 · 1,410 participants · NA
An Evaluation of the Pink Cloud Application in Post- Treatment Substance Use Disorder Support
- NCT07222566 · 1,410 participants · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI